Assessment of tumor mutational burden through a simple blood test could help to identify which patients are most likely to benefit from immunotherapy, but optimal cutoffs are not well established.
References
Peters, S. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01933-w (2022).
Kasi, P. M. ASCO Daily News (October 2020); https://go.nature.com/3C2v5g3
Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. Cancer Cell 39, 154–173 (2021).
Chalmers, Z. R. et al. Genome Med. 9, 34 (2017).
Friedlaender, A. et al. Front. Oncol. 10, 142 (2020).
Strickler, J. H., Hanks, B. A. & Khasraw, M. Clin Cancer Res. 27, 1236–1241 (2021).
Chen, E. X. et al. JAMA Oncol. 6, 831–838 (2020).
Marabelle, A. et al. Lancet Oncol. 21, 1353–1365 (2020).
Malla, M., Loree, J. M., Kasi, P. M. & Parikh, A. R. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.02615 (2022).
Chan, T. A. et al. Ann. Oncol. 30, 44–56 (2019).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kasi, P.M. Liquid biopsies and tumor mutational burden: the cutoff conundrum. Nat Med 28, 1753–1754 (2022). https://doi.org/10.1038/s41591-022-01999-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01999-6
- Springer Nature America, Inc.